In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quell Therapeutics Limited

https://quell-tx.com/

Latest From Quell Therapeutics Limited

Downturn Hit UK Biotech In 2023 But New Pension Funds Could Fuel Growth

Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.

Companies Deals

Can AstraZeneca Sustain Sector-Beating Growth? Its Buying Spree Could Help

AstraZeneca has maintained sector-beating growth for five years, but is looking to a new wave of bolt-on acquisitions and licensing deals to sustain that trajectory beyond 2030.

Companies Strategy

Eisai And Eli Lilly Triumph At The 19th Annual Scrip Awards

Eisai and Lilly were the biggest winners at the 19th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.

Companies Commercial

Investors Impressed With Dualyx Tregs Plans

The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001, which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."

Financing Immune Disorders
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register